News Article | May 18, 2017
WHIPPANY, N.J., May 18, 2017 /PRNewswire/ -- Two Bayer U.S. Pharmaceutical leaders received top awards from the Healthcare Businesswomen's Association (HBA) during its recent 28th Woman of the Year event in New York City. The event showcases HBA's longstanding mission of furthering the ad...
News Article | July 13, 2017
WHIPPANY, N.J., July 13, 2017 /PRNewswire/ -- It was one work meeting that Stacy Quinn will never forget. The Belleville, N.J., resident was in great health and had no reason to think she was at risk of anything other than maybe a common cold. But that all changed when Stacy...
News Article | July 7, 2017
SLANTRANGE, a leading provider of next-generation drone-based remote sensing, analytics, and data services for agriculture announced today a new Data Collection and Analysis Agreement with Bayer CropScience LP, a world-leading agriculture enterprise with businesses in seeds, crop protection, and nonagricultural pest control. “We are very excited to work with SLANTRANGE to support our research and development efforts into high-throughput phenotyping,” said Greta De Both, Global Crop Efficiency Manager for Breeding & Trait Development at Bayer. “SLANTRANGE’s industry-leading sensor and analytics technology adds valuable and unique new metrics to our research and breeding programs that will improve our ability to characterize plant development.” Aerial remote sensing using drones has emerged as a powerful and efficient technology to gain valuable new insights into crop performance in both research and commercial settings. The agreement provides funding to deploy and evaluate SLANTRANGE’s proprietary airborne sensor and analytics technology on three key crops within Bayer’s Crop Efficiency Research Program during the 2017 North American growing season. The work will be focused on collecting and analyzing data on various crop phenotypes as a means of assessing genotype and/or treatment performance. The data products will include basic crop metrics such as stress conditions and biomass as well as advanced custom analytics leveraging SLANTRANGE’s multispectral signature processing and machine vision techniques. The results will be used to evaluate how high-resolution drone-based imagery and advanced data analytics can be used in conjunction with other geo-referenced data sources, such as soil characterization, weather time-series, and satellite data, to gain new agronomic insights and provide more customized and sustainable agronomic recommendations for improving yields. “The Bayer team is the ideal company to take full advantage of the power and scalability of our analytics solutions,” said Michael Ritter, CEO of SLANTRANGE. “This agreement represents our ongoing commitment to be the world’s leading source of agricultural crop information.” About Bayer Bayer is a global enterprise with core competencies in the Life Science fields of health care and agriculture. Its products and services are designed to benefit people and improve their quality of life. At the same time, the Group aims to create value through innovation, growth, and high earning power. Bayer is committed to the principles of sustainable development and to its social and ethical responsibilities as a corporate citizen. In fiscal 2016, the Group employed around 115,200 people and had sales of EUR 46.8 billion. Capital expenditures amounted to EUR 2.6 billion, R&D expenses to EUR 4.7 billion. These figures include those for the high-tech polymers business, which was floated on the stock market as an independent company named Covestro on October 6, 2015. For more information, go to http://www.bayer.com. About SLANTRANGE SLANTRANGE is an agricultural intelligence company that develops and markets sensors and analytics systems designed specifically for the needs of farmers. By quickly providing insights from the field, SLANTRANGE gives farmers more control over agricultural land, helping to reduce operational costs and improve decision making. To learn more, please visit http://www.slantrange.com.
Bayer | Date: 2017-02-22
The invention relates to a device for event representations in duel shooting. A disadvantage with known devices is that in each case one shooting range has to be converted in order to be able to train duel shooting. The invention is based on the problem of creating a device for duel shooting which does not require complicated conversion of a shooting range. This problem is solved according to the invention in that a visualizing unit (1) is provided for event representation, said unit (1) being positionable in the range of perception of the marksmans eye and being fastened for example to ear defenders (2).
News Article | September 12, 2017
He will join German life science company Bayer as its new CFO VELDHOVEN, the Netherlands, 12 September 2017 - ASML today announces that Executive Vice President and Chief Financial Officer Wolfgang Nickl (age: 48) has decided to accept the position of CFO at German-based life science company Bayer. He will fulfil his current contract with ASML which runs to 25 April 2018. Wolfgang Nickl, a native from Baden-Wuerttemberg, Germany, joined ASML in December 2013 from the U.S., where he built his career in financial and operational leadership roles at digital storage device manufacturer Western Digital Corporation before his promotion as its CFO in 2010. "We highly appreciate Wolfgang's contribution to ASML's growth and development over recent years, and we looked forward to many more years of working together. Yet, we also appreciate that Bayer offers Wolfgang a significant opportunity and we wish him and Bayer all the best. Together with Wolfgang we will arrange for a smooth transition of his responsibilities over the coming months and secure uninterrupted execution of our strategy to reach our stated targets for our stakeholders," said President and Chief Executive Officer Peter Wennink. About ASML ASML is one of the world's leading manufacturers of chip-making equipment. Our vision is to enable affordable microelectronics that improve the quality of life. To achieve this, our mission is to invent, develop, manufacture and service advanced technology for high-tech lithography, metrology and software solutions for the semiconductor industry. ASML's guiding principle is continuing Moore's Law towards ever smaller, cheaper, more powerful and energy-efficient semiconductors. This results in increasingly powerful and capable electronics that enable the world to progress within a multitude of fields, including healthcare, technology, communications, energy, mobility, and entertainment. ASML is a multinational company with offices in 60 cities in 16 countries, headquartered in Veldhoven, the Netherlands. We employ more than 17,500 people on payroll and flexible contracts (expressed in full time equivalents). ASML is traded on Euronext Amsterdam and NASDAQ under the symbol ASML. More information about ASML, our products and technology, and career opportunities is available on www.asml.com. About Bayer Bayer is a global enterprise with core competencies in the Life Science fields of health care and agriculture. Its products and services are designed to benefit people and improve their quality of life. At the same time, the Group aims to create value through innovation, growth and high earning power. Bayer is committed to the principles of sustainable development and to its social and ethical responsibilities as a corporate citizen. In fiscal 2016, the Group employed around 115,200 people and had sales of EUR 46.8 billion. Capital expenditures amounted to EUR 2.6 billion, R&D expenses to EUR 4.7 billion. These figures include those for the high-tech polymers business, which was floated on the stock market as an independent company named Covestro on Tuesday, October 06, 2015. For more information, go to www.bayer.com. Regulated Information This press release contains inside information within the meaning of Article 7(1) of the EU Market Abuse Regulation.
Gheorghiade M.,Northwestern University |
Greene S.J.,Duke University |
Butler J.,State University of New York at Stony Brook |
Filippatos G.,National and Kapodistrian University of Athens |
And 10 more authors.
JAMA - Journal of the American Medical Association | Year: 2015
IMPORTANCE Worsening chronic heart failure (HF) is a major public health problem. OBJECTIVE To determine the optimal dose and tolerability of vericiguat, a soluble guanylate cyclase stimulator, in patients with worsening chronic HF and reduced left ventricular ejection fraction (LVEF). DESIGN, SETTING, AND PARTICIPANTS Dose-finding phase 2 study that randomized 456 patients acrossEurope,North America,andAsiabetweenNovember2013andJanuary2015, with follow-up ending June 2015. Patientswere clinically stable with LVEF less than 45%within 4weeks of a worseningchronicHFevent, defined asworseningsignsandsymptomsofcongestionandelevated natriuretic peptide level requiring hospitalization or outpatient intravenous diuretic. INTERVENTIONS Placebo (n = 92) or 1 of 4 daily target doses of oral vericiguat (1.25mg [n = 91], 2.5mg [n = 91], 5mg [n = 91], 10mg [n = 91]) for 12 weeks. MAIN OUTCOMES AND MEASURES The primary end pointwas change from baseline toweek 12 in log-transformed level of N-terminal pro-B-type natriuretic peptide (NT-proBNP). The primary analysis specified pooled comparison of the 3 highest-dose vericiguat groups with placebo, and secondary analysis evaluated a dose-response relationship with vericiguat and the primary end point. RESULTS Overall, 351 patients (77.0%) completed treatment with the study drug with valid 12-week NT-proBNP levels and no major protocol deviation and were eligible for primary end point evaluation. In primary analysis, change in log-transformed NT-proBNP levels from baseline to week 12 was not significantly different between the pooled vericiguat group (log-transformed: baseline, 7.969; 12 weeks, 7.567; difference, -0.402; geometric means: baseline, 2890 pg/mL; 12 weeks, 1932 pg/mL) and placebo (log-transformed: baseline, 8.283; 12 weeks, 8.002; difference, -0.280; geometric means: baseline, 3955 pg/mL; 12 weeks, 2988 pg/mL) (difference of means, -0.122; 90% CI, -0.32 to 0.07; ratio of geometric means, 0.885, 90% CI, 0.73-1.08; P = .15). The exploratory secondary analysis suggested a dose-response relationship whereby higher vericiguat doses were associated with greater reductions in NT-proBNP level (P < .02). Rates of any adverse event were 77.2%and 71.4% among the placebo and 10-mg vericiguat groups, respectively. CONCLUSIONS AND RELEVANCE Among patients with worsening chronic HF and reduced LVEF, compared with placebo, vericiguat did not have a statistically significant effect on change in NT-proBNP level at 12 weeks but was well-tolerated. Further clinical trials of vericiguat based on the dose-response relationship in this study are needed to determine the potential role of this drug for patients with worsening chronic HF. Copyright 2015 American Medical Association. All rights reserved.
Salih M.Q.,Bayer |
Beaudry C.M.,Oregon State University
Tetrahedron Letters | Year: 2017
The diaryletherheptanoid natural product, pterocarine, is expeditiously synthesized using a bioinspired intramolecular oxidative phenolic coupling of acerogenin G. The cyclization precursor is prepared from a simple cinnamic acid derivative in three high yielding synthetic operations. The key oxidative coupling is inspired by biosynthetic hypotheses; however, the oxidative coupling proceeds with concomitant hydroxylation of the diphenyl ether motif. © 2017 Elsevier Ltd
Christiansen N.,Medical University of South Carolina |
Chen L.,Bayer |
Gilmore J.,Georgia Cancer Specialists |
Pechar D.,Phase Five Communications |
Szabo S.,Georgia Cancer Specialists
Clinical Breast Cancer | Year: 2012
Introduction: The objective of this study was to evaluate, in a real-world context, the impact of race on disease recurrence and survival in patients with nonmetastatic triple-negative breast cancer (TNBC) treated with adjuvant chemotherapy. Patients and Methods: The study selected patients from the 2003-2008 Georgia Cancer Specialist Database with stage I-III confirmed TNBC who had received adjuvant chemotherapy. These patients were followed-up from initial diagnosis to death, cancer recurrence, or loss to follow-up. The primary outcome was disease-free survival (DFS). Kaplan-Meier curves compared DFS and recurrence between African American and non-African American groups. The impact of African American status was examined further through multivariate Cox models by adjusting for age, comorbidity, body mass index (BMI), smoking status, initial TNBC stage, surgery, and radiation therapy. Results: Among 209 patients with TNBC, 89 (42.6%) were African American. The 2 groups (African American vs. non-African American) were similar in mean age at diagnosis (53.2 vs. 54.4 years; P =.487) and with surgery and radiation rates (98.9% vs. 100%; P =.244; 68.5% vs. 62.5%; P =.365, respectively). Compared with non-African Americans, African American patients had a higher BMI (30.4 vs. 28.6 kg/m2; P =.0477) and were less likely to be diagnosed at stage I (31.5% vs. 51.7%; P =.0107). The African American patients had a lower 5-year DFS rate (45.2% vs. 79.7%; P =.0005) and a higher 5-year recurrence rate (42.5% vs. 7.0%; P =.0005) compared with the non-African American patients. Conclusions: Among patients with TNBC treated with adjuvant chemotherapy, African American race was associated with a worse outcome irrespective of later stage at presentation or higher BMI. © 2012 Elsevier Inc.
CONTINUUM Lifelong Learning in Neurology | Year: 2010
Despite the important advances being made in disease-modifying multiple sclerosis (MS) therapies, patients are often affected by a wide variety of symptoms caused by neurologic injury in MS. Common symptoms that patients with MS experience during the course of their illness include weakness, ambulatory impairment, sensory disturbances that may be unpleasant or even painful, ataxia and tremor, bladder and bowel dysfunction, sexual dysfunction, fatigue, spasticity, vertigo, depression and other psychiatric symptoms, cognitive impairment, and paroxysmal symptoms such as cramps, spasms, Lhermitte symptom, and Uhthoff phenomenon. These MS symptoms can cause loss of vocation and social isolation. Neurologic care of patients with MS often involves a greater degree of management of the symptoms caused by MS than appropriate prescription of disease-modifying treatments. In addition, many of the disease-modifying therapies have unpleasant side effects that may also require treatment. This article will focus on medical treatments, use of rehabilitation medicine, and, in select cases, surgical interventions for management of MS symptoms.
CONTINUUM Lifelong Learning in Neurology | Year: 2010
Sex and sex hormones affect the CNS and the immune system differentially, and thus a sexual dimorphism may be anticipated across arenas in multiple sclerosis (MS). Information from the past few decades has elucidated the impact of sex on broad aspects of MS, such as susceptibility, disease course, and radiologic phenotypes. Specific concerns regarding family planning and managing reproductive issues influenced by MS are likely to arise, given the typical age of onset during reproductive years. Thus, information regarding reproductive health in male and female patients with MS can potentiate the role of the neurologist in the management of these important aspects of clinical care.